PASITHEA THERAPEUTICS CORP. Finite-Lived Intangible Asset, Expected Amortization, after Year Five
PASITHEA THERAPEUTICS CORP. (KTTA) had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $630.17 thousand as of 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2026-05-15
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $630.17K.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $630.17K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $1.26M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $1.26M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five |
|---|---|
| 2026-03-31 | $630.17K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $630.17K 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.26M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.26M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $1.26M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.26M 10-K · filed 2025-03-24 |
| 2024-09-30 | $1.89M 10-Q · filed 2024-11-13 |
| 2023-12-31 | $1.89M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |